New Analysis of SOLOIST-WHF Trial Underscores Sotagliflozin’s Effect on Reducing Recurrent Heart Failure Events
October 02, 2022 13:00 ET
|
Lexicon Pharmaceuticals, Inc.
Data presented at the Heart Failure Society of America annual scientific meetingNew analysis adds to growing body of evidence in support of the use of sotagliflozin, an investigational dual SGLT1 and...
Lexicon Pharmaceuticals Highlights Scientific and Medical Presentations Relating to Its Successful Phase 2 Proof-Of-Concept Study of LX9211 in Painful Diabetic Neuropathy
September 20, 2022 08:59 ET
|
Lexicon Pharmaceuticals, Inc.
Poster and Oral Presentation at PAINWeek Describing a Novel Mechanism of Action for Neuropathic Pain Poster at International Association for the Study of Pain (IASP) World Congress on Pain Describing...
Lexicon Pharmaceuticals Highlights Publications Relating to Sotagliflozin's Differentiated Dual SGLT1 and SGLT2 Mechanism of Action and Potential Implications for Cardiovascular Disease
August 22, 2022 16:05 ET
|
Lexicon Pharmaceuticals, Inc.
Results to be Presented at the European Society for Cardiology Congress Demonstrate Differential Effects During Endothelial Dysfunction in Cell Studies Recent Publication in the Journal Diabetes...
Lexicon Announces Full Exercise and Closing of Options to Purchase Additional Shares in Connection with Previously Announced Public Offering and Concurrent Private Placement
August 05, 2022 16:59 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the issuance and sale of an additional 2,526,540 shares of its common...
Lexicon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
August 02, 2022 16:01 ET
|
Lexicon Pharmaceuticals, Inc.
Sotagliflozin New Drug Application for Heart Failure Accepted for Review by FDA,with PDUFA Action Date Anticipated in May 2023 LX9211 Phase 2 Clinical Proof-of-Concept Achieved in Painful Diabetic...
Lexicon Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 2, 2022
July 29, 2022 08:00 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, July 29, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its second quarter 2022 financial results on Tuesday, August 2, 2022 after the...
Lexicon Announces Pricing of $85.0 Million Public Offering and Concurrent Private Placement
July 28, 2022 07:00 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, July 28, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the pricing of its previously announced underwritten public offering...
Lexicon Announces Proposed Public Offering Of Common Stock
July 27, 2022 16:01 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, July 27, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced that it has commenced an underwritten public offering to offer and...
Lexicon Announces FDA Acceptance of New Drug Application for Sotagliflozin to Treat Heart Failure
July 27, 2022 07:59 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, July 27, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review and...
Lexicon Announces Positive Top-Line Results From Phase 2 Proof-Of-Concept Study Of LX9211 In Painful Diabetic Neuropathy
June 29, 2022 16:01 ET
|
Lexicon Pharmaceuticals, Inc.
Study Supports Translation of Potential New Mechanism of Action for Neuropathic Pain and Advancement of LX9211 Development in Painful Diabetic Neuropathy Conference Call and Webcast at 8:00 a.m....